Results 11 to 20 of about 317,548 (356)

Record low 2022 Antarctic sea ice led to catastrophic breeding failure of emperor penguins

Communications Earth & Environment, 2023
The spring season of 2022 saw record low sea ice extent in Antarctica that persisted throughout the year. At the beginning of December, the Antarctic sea ice extent was tracking with the all-time low set in 2021. The greatest regional negative anomaly of
P. Fretwell, A. Boutet, N. Ratcliffe
semanticscholar   +1 more source

Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR‐Preserved trial

European Journal of Heart Failure, 2023
In the EMPEROR‐Preserved trial, empagliflozin improved clinical outcomes of patients with heart failure (HF) with preserved ejection fraction. In this pre‐specified analysis, we aim to study the effect of empagliflozin on cardiovascular and kidney ...
Abhinav Sharma, J. Ferreira, F. Zannad, S. Pocock, G. Filippatos, E. Pfarr, M. Petrini, B. Kraus, C. Wanner, M. Packer, J. Butler, S. Anker   +11 more
semanticscholar   +1 more source

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme

European Heart Journal, 2022
Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse patient populations, but their mechanism of action requires further study.
F. Zannad, J. Ferreira, J. Butler, G. Filippatos, J. Januzzi, M. Sumin, M. Zwick, Maral Saadati, S. Pocock, N. Sattar, S. Anker, M. Packer   +11 more
semanticscholar   +1 more source

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial

European Heart Journal, 2022
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction.
W. Doehner, S. Anker, J. Butler, F. Zannad, G. Filippatos, J. Ferreira, A. Salsali, Carolyn Kaempfer, M. Brueckmann, S. Pocock, J. Januzzi, M. Packer   +11 more
semanticscholar   +1 more source

The Emperor's New Markov Blankets [PDF]

Behavioral and Brain Sciences, 2021
The free energy principle, an influential framework in computational neuroscience and theoretical neurobiology, starts from the assumption that living systems ensure adaptive exchanges with their environment by minimizing the objective function of ...
J. Bruineberg, K. Dołęga, Joe E. Dewhurst, Manuel Baltieri   +3 more
semanticscholar   +1 more source

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Circulation, 2021
Supplemental Digital Content is available in the text. Background: Patients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life.
J. Butler, G. Filippatos, T. Jamal Siddiqi, M. Brueckmann, M. Böhm, V. Chopra, João Pedro Ferreira, J. Januzzi, S. Kaul, I. Piña, P. Ponikowski, Sanjiv J. Shah, M. Senni, O. Vedin, S. Verma, B. Peil, S. Pocock, F. Zannad, M. Packer, S. Anker   +19 more
semanticscholar   +1 more source

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

European Heart Journal, 2021
Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with ...
J. Butler, S. Anker, G. Filippatos, M. Khan, J. Ferreira, S. Pocock, N. Giannetti, J. Januzzi, I. Piña, C. Lam, P. Ponikowski, N. Sattar, S. Verma, M. Brueckmann, W. Jamal, O. Vedin, B. Peil, C. Zeller, F. Zannad, M. Packer   +19 more
semanticscholar   +1 more source

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

European Heart Journal, 2022
Aims Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some studies suggested that sodium-glucose cotransporter 2 inhibitors reduce hyperkalaemia, an effect that may
J. Ferreira, F. Zannad, J. Butler, Gerasimos Filipattos, I. Ritter, E. Schüler, B. Kraus, S. Pocock, S. Anker, M. Packer   +9 more
semanticscholar   +1 more source

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.

Journal of the American College of Cardiology, 2021
BACKGROUND Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clinical course of patients with heart failure and reduced ejection fraction.
J. Ferreira, F. Zannad, S. Pocock, S. Anker, J. Butler, G. Filippatos, M. Brueckmann, W. Jamal, D. Steubl, E. Schueler, M. Packer   +10 more
semanticscholar   +1 more source

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

European Heart Journal, 2021
Aims We evaluated the influence of sacubitril/valsartan on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patients with heart failure and a reduced ejection fraction.
M. Packer, S. Anker, J. Butler, G. Filippatos, J. Ferreira, S. Pocock, H. Rocca, S. Janssens, H. Tsutsui, Jian Zhang, M. Brueckmann, W. Jamal, Daniel Cotton, T. Iwata, J. Schnee, F. Zannad   +15 more
semanticscholar   +1 more source